Update on the COX-2 Inhibitor and
NSAID Environment in Canada
 |
This study will explore
ongoing market changes
since the Vioxx withdrawal
in September, 2004.
|
__________________________________________________________________
Source insights to key questions including…
• The role of OTC medication in the management of arthritic conditions
• Current safety perceptions in relation to the COX-2 Inhibitor and NSAID drug classes
• Changes in prescribing behaviour since the identification of Vioxx safety concerns
• Use of COX-2 Inhibitors and NSAID in acute pain, osteoarthritis and rheumatoid arthritis
• Future prescribing intentions
• Physician awareness of new products and their impact on prescribing habits
• The level & components of "noise" in the market
The final deliverables will highlight comparisons with data generated from the Spring 2005 COX-2 Inhibitor and NSAID study, where possible.
Timing
- The study report is available for purchase
Target Participants
- Sample size of 300 GP's, nationally distributed +/- 5.7% margin of error, 19 times out of 20
- Sample of 54 Internal Medicine specialists, nationally distributed +/- 13.3% margin of error, 19 times out of 20
Cost
For more information or to order the study, please email
support@mdanalytics.ca or call 1-866-617-0741